T he number of persons living with end-stage kidney disease continues to increase worldwide. Kidney transplantation provides marked benefits, including increased longevity and quality of life at lower cost than dialysis, but most patients with end-stage kidney disease die before kidney transplantation due to increasing scarcity of donor organs. 1 Although xenotransplantation from pigs could theoretically provide an unlimited supply of organs, the most important obstacles include hyperacute rejection due to the presence of preformed antibodies in human recipients against xenograft antigens and the potential for infection by pathogens that are endogenous to pigs. Substantial progress has been made in engineering genetically modified pigs through gene knockout technology to produce organs that are less likely to elicit severe rejection, and advances in immunomodulatory medications have markedly improved survival of porcine kidneys and islets transplanted in nonhuman primates. 2, 3 Unfortunately, the intensive immunosuppressive therapy that will likely be required to ensure survival of xenografts will also increase the risk of de novo infection and reactivation of latent infections.
Viruses are the most likely microorganisms to be transferred to a human recipient through a porcine allograft. Although the transmission of viruses between pigs can be minimized by preventing contact between animals and by immunization or treatment with antiviral medications, endogenous retroviruses (ERVs) are encoded within the genomes of pigs and nearly all mammalian species and are therefore not amenable to such measures. Retroviruses are RNA viruses that reverse transcribe their RNA to DNA, which becomes integrated into the genomic DNA of host cells. If a retrovirus becomes integrated in the genome of germline lineage cells, it can be vertically transmitted to the genome of subsequent offspring, thereby becoming an ERV. Pig genomes encode several porcine ERVs (PERVs), which can produce viruses that are capable of infecting human cells in vitro. 4 Although there have been no confirmed infections with PERVs in humans exposed to pig-derived cells or tissues via various modes of exposure, concerns about the possible transmission of these viruses to immunosuppressed human recipients remain an important barrier to progress in xenotransplantation.
Investigators have
proposed several approaches to minimize the risk of PERV transmission to human xenotransplant recipients, including the use of pathogen-free pig herds (e.g., Auckland island pigs from New Zealand), vaccination of human recipients before transplantation, and generating genetically modified pigs expressing small, interfering RNA designed to suppress PERV gene expression. 5 In 2015, Yang et al. 6 used clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR-associated protein 9 (Cas9) technology to inactivate all PERVs in a porcine kidney cell line. The CRISPR-Cas9 system was discovered in bacteria, where it is part of the immune response to bacteriophages and plasmids. A segment of foreign DNA is integrated into the bacterial genome at CRISPR loci, and then transcribed into RNA that complexes with the Cas9 endonuclease to target complementary sequences of foreign DNA for doublestrand cleavage. CRISPR-Cas9 technology has since been adapted by investigators to introduce permanent, targeted mutations in the genomes of live cells both in vitro and in vivo. In the 2015 study, Yang et al. used this technology to mutate a highly conserved reverse transcriptase sequence that is shared among all known PERVs and is essential for PERV function. This approach led to a 1000-fold decrease in the ability of porcine kidney cells to infect human kidney cells with PERVs in vitro, but it remained unclear whether it would be successful in inactivating PERVs in pigs in vivo. 6 The same group has now extended their work as reported in a recent issue of Science. 7 First, the investigators showed that coincubation with an unmodified porcine kidney cell line led to infection of a human kidney cell line with PERVs and that these human cells could then transmit PERVs to other human kidney cells, suggesting that pig-to-human transmission of PERVs is theoretically possible.
The authors then set out to generate pigs with inactivation of all PERVs. They first generated a primary fibroblast cell line from a fetal pig and designed guide RNAs to mutate the sequence encoding the conserved reverse transcriptase catalytic site using a similar approach as in their previous study. The authors were able to overcome technical issues resulting in poor growth of CRISPR-Cas9-modified cells by treating them with growth factors and apoptosis inhibitors, allowing for the expansion of cells with successful mutation of all PERV loci. Importantly, there was no evidence of viral shedding, and karyotyping confirmed that chromosomal abnormalities observed in some of the modified cells corresponded to PERV cutting sites, suggesting a lack of "off target" effects of CRISPR-Cas9. After karyotyping to rule out large chromosomal deletions induced by CRISPR-Cas9, selected pig embryos were generated by somatic cell nuclear transfer from fibroblasts to enucleated pig oocytes, and embryos were transferred into surrogate sows. DNA sequencing of fetuses at pregnancy day 50 demonstrated inactivation of 100% of PERV sequences, and the number of PERV sequences encoded in the pigs' genomes had remained stable. Karyotyping did not identify chromosomal abnormalities. Using this approach, the investigators generated 37 PERVinactivated pigs (Figure 1 ) that were born to 17 sows. Fifteen of the pigs were alive at the time the manuscript was written, the oldest of which was 4 months old.
This study provides exciting evidence that inactivation of PERVs using CRISPR-Cas9 may be a feasible approach to reduce or eliminate the risk of PERV transmission to human recipients of porcine organs. Interestingly, in many mammalian species, ERV envelope proteins are important for placental syncytiotrophoblast formation, 8 but the results of this study suggest that PERV reverse transcriptase function is not required for normal placental function in pigs. Although the authors report that 1 PERV-inactivated pig was alive and healthy at 4 months of age, it appears that more than half of the genetically modified animals died or were killed before this age. Ongoing phenotypic studies are needed to better characterize the PERV-inactivated pigs, particularly with respect to key organ function as they age. Nonetheless, this study represents an exciting step toward addressing one of the major barriers to xenotransplanation. Although important hurdles remain before porcine organs can be transplanted in humans, the rapid improvements in the outcomes of kidney xenografts from genetically modified pigs into nonhuman primates suggest that clinical trials in humans may occur in the foreseeable future.
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